Happy Tuesday. Here’s what’s steaming and what’s stalling today:
P.S. Wall Street’s 150% Opportunity: This Wednesday, March 11, two under-the-radar stock picks will be revealed — including one analysts believe could surge 150%+ in the year ahead. Only subscribers will see the names. Unlock them here.
A note from our sponsors...
Buffett's $114 Secret In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account." Today, that single, $114 investment would be worth over $15 million. Your bank never told you about this. Click Here to See How It Works🔥 HOT: Mortgage REIT Rithm Capital (RITM) looks poised to outperform. Why? A few reasons: 1) The company is riding positive sentiment, with several REITs raising full-year FFO outlooks during earnings season—Rithm is benefiting from this broader tailwind. 2) Recent analysis suggests Wall Street's view on the stock has aligned more favorably, a notable shift given the sector's volatility. 3) Currently trading under $10, the stock offers compelling value in a market where yield-hungry investors are reassessing fixed-income alternatives 4) The stock was recently upgraded to a Zen Rating of B (Buy), meaning it currently ranks in the top 20% of stocks based on a 115-factor review. Looking at the Component Grades that make up the overall grade, it scores particularly well with a B Grade for Sentiment and Value. The bottom line? Buy. Despite some recent weakness (down slightly this week), Rithm's strong value metrics and positive sentiment make it an attractive play for income-focused investors willing to navigate the mortgage REIT landscape.
🥶 NOT: Diagnostic and research company Guardant Health (GH) appears to be hitting a rough patch. The stock has slipped about 10% in the past month, despite positive news around its Shield blood test for colorectal cancer; on top of that, the stock was just downgraded to a C (Hold) Zen Rating, with Component Grades that struggle to suggest a turnaround on the horizon. GH earns a D Grade for Sentiment, and C Grades in every other category — unimpressive to say the least. True, the company's FDA-approved Shield test has real potential, but with sentiment ice-cold and the stock losing momentum, it's a wait-and-see situation until fundamentals catch up to the narrative.
🔥 HOT: Semiconductor maker Marvell Technology (MRVL) isn’t just blowing smoke — it appears to be on fire (in a good way). The stock surged 18% on Friday following blowout fiscal Q4 results that sent Wall Street scrambling to raise price targets (See the most up-to-date targets and forecasts here.) The earnings beat wasn't just a beat; it was a reminder that AI infrastructure demand is very much alive, evidenced by the fact that the company just launched 1.6 Terabit ZR/ZR+ optical interconnect solutions using proprietary 2nm DSPs, targeting the hyperscale AI and cloud data center market. The stock was recently upgraded to a Zen Rating of B (Buy), with a particularly strong Financials grade of B. The verdict? While MRVL hasn’t been as showy as big players like NVDA and AVGO, momentum is building, and with analyst upgrades flowing, and a strategic push into high-bandwidth AI connectivity, Marvell appears positioned for a strong run.
🥶 NOT: Specialty industrial machinery maker CSW Industrials (CSW) is losing steam. Despite a recent rally, the stock has lost 10% in the past week, a move that has inspired caution in investors and analysts alike, with recent analysis suggesting shares are getting expensive relative to fundamentals. The company's aggressive acquisition strategy, while growth-oriented, has pushed valuation metrics into stretched territory, raising questions about whether the premium is justified given execution risks and integration challenges ahead. The stock currently only earns a C (Hold) Rating from the Zen Ratings, placing it in the middle of the pack. It struggles with an F Grade for Sentiment and a D Grade for Momentum. The verdict? CSW is a quality name in a strong industry (ranks 9th out of 68 in Specialty Industrial Machinery), but this is a wait-and-see situation. Better to watch from the sidelines until the risk-reward rebalances.
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.